Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats
- 30 April 2010
- journal article
- Published by Elsevier BV in Pharmacological Research
- Vol. 61 (4), 321-328
- https://doi.org/10.1016/j.phrs.2009.11.005
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- The endocannabinoid system: From biology to therapyPharmacological Research, 2009
- The endocannabinoid system and pivotal role of the CB 2 receptor in mouse spermatogenesisProceedings of the National Academy of Sciences of the United States of America, 2009
- Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory painNeuropharmacology, 2008
- Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptorsBritish Journal of Pharmacology, 2007
- Selective CB2 up‐regulation in women affected by endometrial inflammationJournal of Cellular and Molecular Medicine, 2007
- Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptorsBritish Journal of Pharmacology, 2007
- Endocannabinoid overactivity and intestinal inflammationGut, 2006
- Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cellsBiochemical Journal, 2005
- Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5British Journal of Pharmacology, 2005
- Cannabinoids and intestinal motility: welcome to CB2 receptorsBritish Journal of Pharmacology, 2004